199739-10-1
Chemical Structure
Paliperidone palmitate
Synonym(s): 9-Hydroxyrisperidone palmitate
- CAS No.: 199739-10-1
- Formula:C39H57FN4O4
- Molecular Weight:664.89
IUPAC Name: 3-(2-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl palmitate
InChIKey: VOMKSBFLAZZBOW-UHFFFAOYSA-N
SMILES: O=C(OC1CCCN(C1=NC(C)=C2CCN3CCC(C4=NOC5=C4C=CC(F)=C5)CC3)C2=O)CCCCCCCCCCCCCCC
Biological Activity: Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Paliperidone palmitate | 99.93% | Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Paliperidone palmitate (Standard) | ≥98% | Paliperidone palmitate (Standard) is the analytical standard of Paliperidone palmitate. This product is intended for research and analytical applications. Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Paliperidone palmitate-d4 | Paliperidone palmitate-d4 (9-Hydroxyrisperidone palmitate-d4) is the deuterium labeled Paliperidone palmitate (HY-A0019A). Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Darville N, et al. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J Control Release. 2016 May 28;230:95-108. [Content Brief]
- [2]. Pertinez H, et al. Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models. bioRxiv [Preprint]. 2024 Mar 6:2024.03.03.583160. [Content Brief]
- [3]. Kwon JS, et al. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30(6):320-328. [Content Brief]
